CN110095605A - A kind of kit for screening of lung cancer - Google Patents
A kind of kit for screening of lung cancer Download PDFInfo
- Publication number
- CN110095605A CN110095605A CN201910347649.3A CN201910347649A CN110095605A CN 110095605 A CN110095605 A CN 110095605A CN 201910347649 A CN201910347649 A CN 201910347649A CN 110095605 A CN110095605 A CN 110095605A
- Authority
- CN
- China
- Prior art keywords
- phosphorylation
- reagent
- lung cancer
- blk
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 43
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 43
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 43
- 238000012216 screening Methods 0.000 title claims abstract description 17
- 230000026731 phosphorylation Effects 0.000 claims abstract description 46
- 238000006366 phosphorylation reaction Methods 0.000 claims abstract description 46
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 33
- 238000001514 detection method Methods 0.000 claims abstract description 30
- 210000004072 lung Anatomy 0.000 claims description 16
- 238000002965 ELISA Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000012188 paraffin wax Substances 0.000 description 7
- 238000004821 distillation Methods 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- 230000008520 organization Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 101000579646 Penaeus vannamei Penaeidin-1 Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/302—Stain compositions
Abstract
The invention discloses a kind of kit for screening of lung cancer, it includes optional for detecting the reagent of phosphorylation BLK expression.The invention also discloses the reagents of detection phosphorylation BLK expression to prepare the purposes in screening lung cancer reagent.Kit of the present invention can effectively judge the risk that crowd to be checked suffers from lung cancer, can be used for the auxiliary diagnosis of clinical lung cancer by the expression of detection phosphorylation BLK, take relevant remedy measures or decision to provide effective foundation for patient, potential applicability in clinical practice is good.
Description
Technical field
The present invention relates to a kind of kit for screening of lung cancer.
Background technique
Lung cancer is that morbidity and mortality growth is most fast, to one of population health and the maximum malignant tumour of life threat.
Many countries all report that the morbidity and mortality of lung cancer obviously increase in the past 50 years, and male lung cancer morbidity and mortality are equal
First of all malignant tumours is accounted for, women disease incidence accounts for second, and the death rate accounts for second.Non-small cell type lung cancer is lung cancer
In one kind, account for about the 80% of all lung cancer, when about 75% Finding case has been in middle and advanced stage, and survival rate is very low within 5 years.Cause
This, it is extremely important to lung cancer progress early stage, quick diagnosis.
The screening of lung cancer, referring to does not have the related indication crowd of lung cancer to carry out routine examination those, before there is symptom
It was found that lung cancer.If the lung cancer molecular marker inside blood can be found, for prompting clinician to take patient early stage
Relevant remedy measures or decision have great importance.
Currently, the diagnosis of lung cancer all relies on greatly In vivo detection lung tissue, but such detection method is complicated for operation,
It is very big to the injury of lungs of patient, and it is likely to result in lung cancer diffusion, there are great risks.Searching is more easy, wound is small,
The detection method of Small side effects is urgently to be resolved.
Phosphorylation BLK is the bone-marrow-derived lymphocyte tyrosine kinases of phosphorylation.It now there are no document report and pass through detection phosphoric acid
Change BLK to detect lung cancer.
Summary of the invention
To solve the above-mentioned problems, small, Small side effects that the present invention provides a kind of wounds, lung cancer detection examination easy to use
Agent box.
The kit for screening of lung cancer of the present invention, it includes optional for detecting the reagent of phosphorylation BLK expression.
Wherein, the reagent is the reagent for detecting phosphorylation BLK expression in serum and/or lung tissue.
Wherein, the reagent of the detection phosphorylation BLK expression is ELISA detection reagent.
Wherein, the reagent of the detection phosphorylation BLK expression is Western-blot detection method reagent.
The present invention also provides the reagents of detection phosphorylation BLK expression to prepare the use in screening lung cancer reagent
On the way.
Wherein, the reagent of the detection phosphorylation BLK expression is ELISA detection reagent.
Wherein, the reagent of the detection phosphorylation BLK expression is Western-blot detection method reagent.
Wherein, the reagent is the reagent for detecting phosphorylation BLK expression in serum and/or lung tissue.
The expression that kit of the present invention passes through detection phosphorylation BLK, it can be determined that crowd to be checked suffers from the risk of lung cancer,
Can be used for the auxiliary diagnosis of clinical lung cancer, kit of the present invention only needs the blood of acquisition sample to be examined, so that it may screening its
Suffer from the risk of lung cancer, wound is small, Small side effects, easy to use, and potential applicability in clinical practice is good.
Obviously, above content according to the present invention is not being departed from according to the ordinary technical knowledge and customary means of this field
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
The specific embodiment of form by the following examples remakes further specifically above content of the invention
It is bright.But the range that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to example below.It is all to be based on above content of the present invention
The technology realized all belongs to the scope of the present invention.
Specific embodiment
The expression of 1 phosphorylation BLK of embodiment and the relationship of lung cancer
One, experimental method
1, clinical data
Patients with lung cancer paraffin section 30 are chosen, distal end control 30 (refers to the distal end normal lung tissue paraffin of patients with lung cancer
Slice, is confirmed as normal tissue apart from cancerous tissue 5cm, and through pathology), essential information is shown in Table 1.
1 clinical elementary information of table
*Note: other include large cell carcinoma, adenosquamous carcinoma, small cell carcinoma.
Paraffin section is compareed to patients with lung cancer paraffin section, remote organization, is carried out using phosphorylation BLK as the immune group of index
Change (IHC).
Phosphorylation BLK antibody: U.S. Affinity company, article No. AF8133 are purchased from；
EnVisionTMHRP secondary antibody, antibody diluent, DAB color developing agent, antigen retrieval buffers, Wash Buffer, immune group
Change pen: being purchased from Dako company, Denmark.
The expression of phosphorylation BLK is detected as follows:
(1) it closes peroxidase: paraffin section being taken to dewax, (dewaxing process is as follows: dimethylbenzene to aquation for dewaxing
I10min → dimethylbenzene II10min → the ethyl alcohol of dehydrated alcohol 5min → 95% ethyl alcohol of 5min → 85% ethyl alcohol of 5min → 75%
After 5min), 3%H is used2O2Solution closes endogenous peroxydase in dark place, is incubated at room temperature 15min；
(2) distilled water rinses: slice is placed in distilled water, is washed 5min/ times on shaking table, altogether three times；
(3) antigen retrieval: slice is put into the EDTA antigen retrieval solution of pH9.0, the water-bath 40min in 98 DEG C of water-baths,
Carry out antigen retrieval；
(4) distilled water rinses: taking out and is sliced, after cooled to room temperature, is washed three times with distillation, then use Wash
Buffer rinsing is primary；
(5) it is incubated for primary antibody: being enclosed tissue with immunohistochemistry pen, phosphorylation BLK antibody working solution (phosphoric acid is added dropwise in circle
Change BLK to mix with antibody diluent 1:150), 4 DEG C of overnight incubations；
(6) distilled water rinses: with distillation washing three times, Wash Buffer rinses primary；
(7) secondary antibody is added dropwise: the secondary antibody working solution of Dako HRP label is added dropwise, is incubated at room temperature 60min；
(8) distilled water rinses: distillation washing 3 times, each 5min；
(9) DAB develops the color: chromogenic substrate DAB is added dropwise, observation colour developing situation, terminates reaction in distilled water under the microscope；
(10) haematoxylin is redyed: slice is put into haematoxylin dye liquor and dyes 2min, after the differentiation of 1% hydrochloride alcohol, and flowing water
Rinse 10min；
(11) it is dehydrated transparent: being sliced, Yu Tongfeng transparent through 75%, 85%, 95%, 100% gradient alcohol dehydration, dimethylbenzene
It is dry in cupboard；
(12) it mounting: with neutral Instant cement mounting, observes under an optical microscope, DP Controller Image Acquisition system
System adopts figure.After adopting figure, immunohistochemistry is given according to the tumour cell staining power and positive area of patients with lung cancer and remote organization
Scoring.
3, immunohistochemistry standards of grading
First according to the form below provides the scoring of tumour cell staining power, positive area:
@Note: it is independently scored tumour cell staining power result by two veteran pathologists
Calculate the product (0-9 point) of the scoring of tumour cell staining power and positive area scoring again, it is specified that:
Phosphorylation BLK expression is negative: 0 point；
Phosphorylation BLK expression is low positive: 1-3 points；
Phosphorylation BLK expression High positive > 3 divides.
4, interpretation of result
Statistical analysis is carried out using SPSS17.0 cancerous lung tissue group and remote organization's control group.
Two, experimental result
Cancerous lung tissue compareed with remote organization in the expression testing result of phosphorylation BLK be shown in Table 2.
The expression of 2 phosphorylation BLK of table
As can be seen from Table 2, the positive expression rate of phosphorylation BLK is 6.7% in the normal tissue of distal end, High positive expression rate is
0%；Phosphorylation BLK positive expression rate in cancerous lung tissue is 93.3%, and High positive expression rate is 60%；Phosphorylation BLK exists
It is significantly increased in cancerous lung tissue, compared with the normal tissue of distal end, phosphorylation BLK expression difference has statistical significance (P <
0.0001)。
As can be seen from the above results, compared with Ai Pang normal lung tissue, the phosphorylation BLK expression of cancerous lung tissue is aobvious
It writes and increases (P < 0.0001), illustrate that lung cancer is positively correlated with phosphorylation BLK expression, the high expression of phosphorylation BLK can be significant
A possibility that lung cancer, is suffered from raising.Since the phosphorylation BLK level of Ai Pang normal lung tissue can reflect the phosphoric acid of Normal Lung tissue
It is horizontal to change BLK, therefore, can be gone out Susceptible population's screening of lung cancer by the expression of the phosphorylation BLK of detection person to be checked
Come.
2 screening lung cancer kit of embodiment and its application method
One, kit forms
Detection kit (50 person-portion):
| Component | Volume |
| Phosphorylation BLK antibody | 100μl |
| EnVisionTMHRP secondary antibody | 10ml |
| Antibody diluent | 10ml |
| DAB color developing agent | 10ml |
| Antigen retrieval buffers | 500ml |
| Wash Buffer* | 500ml |
| Immunohistochemistry pen | 1 |
Note: it is based on 100 μ l that all kinds of experiment reagents, which are added dropwise, by every slice in this kit, and specific dosage can be according to tissue size
Appropriate increase and decrease.
Two, the application method of kit
By sample to be examined lung tissue, paraffin section is prepared, as detection sample, detects phosphorylation as follows
The expression of BLK:
(1) it closes peroxidase: paraffin section being taken to dewax, (dewaxing process is as follows: dimethylbenzene to aquation for dewaxing
I10min → dimethylbenzene II10min → the ethyl alcohol of dehydrated alcohol 5min → 95% ethyl alcohol of 5min → 85% ethyl alcohol of 5min → 75%
After 5min), endogenous peroxydase is closed in dark place with 3%H2O2 solution, is incubated at room temperature 15min；
(2) distilled water rinses: slice is placed in distilled water, is washed 5min/ times on shaking table, altogether three times；
(3) antigen retrieval: slice is put into the EDTA antigen retrieval solution of pH9.0, the water-bath 40min in 98 DEG C of water-baths,
Carry out antigen retrieval；
(4) distilled water rinses: taking out and is sliced, after cooled to room temperature, is washed three times with distillation, then use Wash
Buffer rinsing is primary；
(5) it is incubated for primary antibody: being enclosed tissue with immunohistochemistry pen, phosphorylation BLK antibody working solution (phosphoric acid is added dropwise in circle
Change BLK to mix with antibody diluent 1: 150), 4 DEG C of overnight incubations；
(6) distilled water rinses: with distillation washing three times, Wash Buffer rinses primary；
(7) secondary antibody is added dropwise: the secondary antibody working solution of Dako HRP label is added dropwise, is incubated at room temperature 60min；
(8) distilled water rinses: distillation washing 3 times, each 5min；
(9) DAB develops the color: chromogenic substrate DAB is added dropwise, observation colour developing situation, terminates reaction in distilled water under the microscope；
(10) haematoxylin is redyed: slice is put into haematoxylin dye liquor and dyes 2min, after the differentiation of 1% hydrochloride alcohol, and flowing water
Rinse 10min；
(11) it is dehydrated transparent: being sliced, Yu Tongfeng transparent through 75%, 85%, 95%, 100% gradient alcohol dehydration, dimethylbenzene
It is dry in cupboard；
(12) it mounting: with neutral Instant cement mounting, observes under an optical microscope, DP Controller Image Acquisition system
System adopts figure.After adopting figure, immunohistochemistry is given according to the tumour cell staining power and positive area of patients with lung cancer and remote organization
Scoring, methods of marking are shown in embodiment 1.
To pulmonary abnormalities person, abnormal position, normal portions tissue can be taken respectively, compare phosphorylation BLK expression, in turn
A possibility that it suffers from lung cancer is evaluated, the auxiliary diagnosis means as clinical lung cancer.
To sum up, kit of the present invention, can be with screening crowd's trials and tribulations lung cancer to be checked by the expression of detection phosphorylation BLK
Risk, can be used for the auxiliary diagnosis of clinical lung cancer, for patient take relevant remedy measures or decision provide effectively according to
According to potential applicability in clinical practice is good.
Claims (8)
1. a kind of screening lung cancer kit, it is characterised in that: it includes optional for detecting the examination of phosphorylation BLK expression
Agent.
2. kit for screening according to claim 1, it is characterised in that: the reagent is for detecting serum and/or lung
The reagent of phosphorylation BLK expression in tissue.
3. kit for screening according to claim 1 or 2, it is characterised in that: the detection phosphorylation BLK expression
Reagent is ELISA detection reagent.
4. kit for screening according to claim 1 or 2, it is characterised in that: the detection phosphorylation BLK expression
Reagent is Western-blot detection method reagent.
5. the reagent of detection phosphorylation BLK expression is preparing the purposes in screening lung cancer reagent.
6. purposes according to claim 5, it is characterised in that: it is described detection phosphorylation BLK expression reagent be
Reagent is used in ELISA detection.
7. purposes according to claim 5, it is characterised in that: it is described detection phosphorylation BLK expression reagent be
Western-blot detection method reagent.
8. according to the described in any item purposes of claim 5~7, it is characterised in that: the reagent be for detect serum and/or
The reagent of phosphorylation BLK expression in lung tissue.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810395698 | 2018-04-27 | ||
| CN201810395698X | 2018-04-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110095605A true CN110095605A (en) | 2019-08-06 |
| CN110095605B CN110095605B (en) | 2020-10-20 |
Family
ID=67446012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910347649.3A Active CN110095605B (en) | 2018-04-27 | 2019-04-26 | Lung cancer screening kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110095605B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012125712A2 (en) * | 2011-03-14 | 2012-09-20 | Respira Health, Llc | Lung tumor classifier for current and former smokers |
| CN106918698A (en) * | 2015-12-25 | 2017-07-04 | 广州瑞博奥生物科技有限公司 | A kind of phospho-AB chip agent box for detecting human receptor tyrosine kinase enzyme |
-
2019
- 2019-04-26 CN CN201910347649.3A patent/CN110095605B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012125712A2 (en) * | 2011-03-14 | 2012-09-20 | Respira Health, Llc | Lung tumor classifier for current and former smokers |
| CN106918698A (en) * | 2015-12-25 | 2017-07-04 | 广州瑞博奥生物科技有限公司 | A kind of phospho-AB chip agent box for detecting human receptor tyrosine kinase enzyme |
Non-Patent Citations (1)
| Title |
|---|
| HONG-REN YU ET AL: "Distinct expressions of immunoglobulin signal related molecules between human Kawasaki disease and BALB/c mice treated with Lactobacillus casei cell wall extract", 《INT J CLIN EXP MED》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110095605B (en) | 2020-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | The combination of the tumor markers suggests the histological diagnosis of lung cancer | |
| Kinsella et al. | Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre-and post-neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience | |
| Khoddami et al. | Correlation between Gleason scores in needle biopsy and corresponding radical prostatectomy specimens: a twelve-year review | |
| Bean et al. | Recent developments in defining microinvasive and early invasive carcinoma of the uterine cervix | |
| Yeon et al. | Comparison of liquid-based cytology (CellPrepPlus) and conventional smears in pancreaticobiliary disease | |
| Wang et al. | Acinar cell cystadenoma of the pancreas: A retrospective analysis of ten-year experience from a single academic institution | |
| Karaarslan et al. | The role of parafibromin, galectin-3, HBME-1, and Ki-67 in the differential diagnosis of parathyroid tumors | |
| Zhang et al. | Verrucous carcinoma of the vulva: a case report and literature review | |
| He et al. | Expression of nestin in ovarian serous cancer and its clinicopathologic significance. | |
| Yildiz et al. | Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies | |
| CN103954761A (en) | Kit for rapid early-to-mid diagnosis of ovarian cancer and detection method thereof | |
| Szade et al. | High-grade non-small cell lung carcinoma: a comparative analysis of the phenotypic profile in small biopsies with the corresponding postoperative material | |
| CN110095605A (en) | A kind of kit for screening of lung cancer | |
| CN110244058A (en) | ENPP1 is preparing the application in high-level serous ovarian cancer diagnosis and prognosis kit | |
| CN110095606A (en) | A kind of kit for screening of lung cancer | |
| CN105954517B (en) | A kind of screening lung cancer kit | |
| CN103969437A (en) | Preparation method of kit for early-to-mid rapid diagnosis of ovarian cancer | |
| CN109212214B (en) | A kind of screening lung cancer kit | |
| Lu et al. | Diagnostic utility of serum Golgi phosphoprotein 3 in bladder cancer patients | |
| CN108088998A (en) | A kind of screening lung cancer kit | |
| CN106383230B (en) | A kind of pulmonary cancer diagnosis kit | |
| CN105929164B (en) | A kind of screening lung cancer kit | |
| Yao et al. | Clinicopathologic correlation of serum tissue polypeptide specific antigen in hepatocellular carcinoma | |
| RU2530557C1 (en) | Differential diagnostic technique for malignant and benign breast pathology | |
| CN116183935B (en) | Molecular marker for predicting prognosis of hepatic portal cholangiocarcinoma and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |